Literature DB >> 11554426

Brain microdialysis and PK/PD correlation of pregabalin in rats.

M R Feng1, D Turluck, J Burleigh, R Lister, C Fan, A Middlebrook, C Taylor, T Su.   

Abstract

Pregabalin [PGB, (S)-3-isobutyl GABA, CI-1008] is a derivative of the inhibitory neurotransmitter g-aminobutyric acid (GABA). It has shown anticonvulsant, analgesia and anxiety activity in animal models. In this report, blood-brain barrier (BBB) influx and efflux of PGB were investigated with microdialysis at efficacious doses in rats. BBB influx (CLin) and efflux (CLout) permeability for pregabalin were 4.8 and 37.2 microL/min/g brain, respectively, following an intravenous infusion to rats. The results indicate that PGB is brain penetrable, supporting its anti-epilepsy and other CNS pharmacology. Significant anticonvulsant action of PGB was detected between 2 and 8 hr post oral dose, which is lag behind ECF drug concentrations lees. A PK/PD link model was used to describe the counter-clockwise hysteresis relationship between pregabalin brain ECF concentration and the anticonvulsant effect in rats. The resulting Ce (concentration in effect compartment) versus effect profile exhibits a sigmoidal curve and the calculated ECe50 and Keo values were 95.3 ng/mL and 0.0092 min-1, respectively. The small Keo value suggests that the effect is not directly proportional to the amount of pregabalin in the ECF compartment possibly due to inherent delay.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11554426     DOI: 10.1007/BF03190385

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  7 in total

1.  The simultaneous estimation of the influx and efflux blood-brain barrier permeabilities of gabapentin using a microdialysis-pharmacokinetic approach.

Authors:  Y Wang; D F Welty
Journal:  Pharm Res       Date:  1996-03       Impact factor: 4.200

2.  Capillary depletion method for quantification of blood-brain barrier transport of circulating peptides and plasma proteins.

Authors:  D Triguero; J Buciak; W M Pardridge
Journal:  J Neurochem       Date:  1990-06       Impact factor: 5.372

3.  A general conceptual model for non-steady state pharmacokinetic/pharmacodynamic data.

Authors:  D Verotta; L B Sheiner
Journal:  J Pharmacokinet Biopharm       Date:  1995-02

4.  Microdialysis calibration using retrodialysis and zero-net flux: application to a study of the distribution of zidovudine to rabbit cerebrospinal fluid and thalamus.

Authors:  Y Wang; S L Wong; R J Sawchuk
Journal:  Pharm Res       Date:  1993-10       Impact factor: 4.200

5.  Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine.

Authors:  L B Sheiner; D R Stanski; S Vozeh; R D Miller; J Ham
Journal:  Clin Pharmacol Ther       Date:  1979-03       Impact factor: 6.875

6.  Transport of gabapentin, a gamma-amino acid drug, by system l alpha-amino acid transporters: a comparative study in astrocytes, synaptosomes, and CHO cells.

Authors:  T Z Su; E Lunney; G Campbell; D L Oxender
Journal:  J Neurochem       Date:  1995-05       Impact factor: 5.372

7.  Gabapentin anticonvulsant action in rats: disequilibrium with peak drug concentrations in plasma and brain microdialysate.

Authors:  D F Welty; G P Schielke; M G Vartanian; C P Taylor
Journal:  Epilepsy Res       Date:  1993-12       Impact factor: 3.045

  7 in total
  8 in total

1.  Extended-release formulations of antiepileptic drugs: rationale and comparative value.

Authors:  Emilio Perucca
Journal:  Epilepsy Curr       Date:  2009 Nov-Dec       Impact factor: 7.500

2.  Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships.

Authors:  Christopher Louizos; Jaime A Yáñez; M Laird Forrest; Neal M Davies
Journal:  J Pharm Pharm Sci       Date:  2014       Impact factor: 2.327

Review 3.  Age-associated physiological and pathological changes at the blood-brain barrier: A review.

Authors:  Franciska Erdő; László Denes; Elizabeth de Lange
Journal:  J Cereb Blood Flow Metab       Date:  2016-11-11       Impact factor: 6.200

4.  Pharmacological Probes to Validate Biomarkers for Analgesic Drug Development.

Authors:  Johannes van Niel; Petra Bloms-Funke; Ombretta Caspani; Jose Maria Cendros; Luis Garcia-Larrea; Andrea Truini; Irene Tracey; Sonya C Chapman; Nicolás Marco-Ariño; Iñaki F Troconiz; Keith Phillips; Nanna Brix Finnerup; André Mouraux; Rolf-Detlef Treede
Journal:  Int J Mol Sci       Date:  2022-07-27       Impact factor: 6.208

5.  The treatment of generalized anxiety disorder with pregabalin, an atypical anxiolytic.

Authors:  Jeffrey R Strawn; Thomas D Geracioti
Journal:  Neuropsychiatr Dis Treat       Date:  2007-04       Impact factor: 2.570

6.  Pregabalin for the management of partial epilepsy.

Authors:  Philippe Ryvlin; Emilio Perucca; Sylvain Rheims
Journal:  Neuropsychiatr Dis Treat       Date:  2008-12       Impact factor: 2.570

7.  Transport of Pregabalin Via L-Type Amino Acid Transporter 1 (SLC7A5) in Human Brain Capillary Endothelial Cell Line.

Authors:  Yu Takahashi; Tomohiro Nishimura; Kei Higuchi; Saki Noguchi; Yuma Tega; Toshiki Kurosawa; Yoshiharu Deguchi; Masatoshi Tomi
Journal:  Pharm Res       Date:  2018-10-29       Impact factor: 4.200

8.  Pregabalin Treatment does not Affect Amyloid Pathology in 5XFAD Mice.

Authors:  Katherine R Sadleir; Jelena Popovoic; Wei Zhu; Cory T Reidel; Ha Do; Richard B Silverman; Robert Vassar
Journal:  Curr Alzheimer Res       Date:  2021       Impact factor: 3.040

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.